» Articles » PMID: 30961518

Nanocrystalization: An Emerging Technology to Enhance the Bioavailability of Poorly Soluble Drugs

Overview
Date 2019 Apr 10
PMID 30961518
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Most of the active pharmaceutical ingredient used in the management of disease have poor water solubility and offer grueling problems in drug formulation development since low solubility is generally associated with poor dissolution characteristics which leads to poor oral bioavailability. The great challenge for the development of a pharmaceutical product is to create its new formulation and drug delivery system to limit solubility problems of existing drug candidate. Limited drug-loading capacity requires a large amount of carrier material to get appropriate encapsulation of the drug, which is another major challenge in the development of pharmaceutical product which could be resolved by developing nanocrystals (NCs). A significant research in the past few years has been done to develop NCs which helps in the delivery of poorly water soluble drugs via different routes. The technology could continue to thrive as a useful tool in pharmaceutical sciences for the improvement of drug solubility, absorption and bioavailability. Many crystalline compounds have pulled in incredible consideration much of the time, due to their ability to show good physical and chemical properties when contrasted with their amorphous counterparts. Nanocrystals have been proven to show atypical properties compared to the bulk. This review article explores the principles of the important nanocrystallization techniques including NCs characterization and its application.

Citing Articles

Nanocrystals for Intravenous Drug Delivery: Composition Development, Preparation Methods and Applications in Oncology.

Chen W, Huang J, Guo Y, Wang X, Lin Z, Wei R AAPS PharmSciTech. 2025; 26(3):66.

PMID: 39979757 DOI: 10.1208/s12249-025-03064-0.


Nanocrystals in Dermal Drug Delivery: A Breakthrough for Enhanced Skin Penetration and Targeted Skin Disorder Treatments.

Alnaim A Pharmaceutics. 2025; 16(12.

PMID: 39771540 PMC: 11676127. DOI: 10.3390/pharmaceutics16121561.


Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches.

Wu K, Kwon S, Zhou X, Fuller C, Wang X, Vadgama J Int J Mol Sci. 2024; 25(23.

PMID: 39684832 PMC: 11642056. DOI: 10.3390/ijms252313121.


Albumin and Polysorbate-80 Coated Sterile Nanosuspensions of Mebendazole for Glioblastoma Therapy.

Patel H, Patel A, Vats M, Patel K AAPS PharmSciTech. 2024; 25(8):271.

PMID: 39586850 DOI: 10.1208/s12249-024-02978-5.


Formononetin-Loaded Self-Microemulsion Drug Delivery Systems for Improved Solubility and Oral Bioavailability: Fabrication, Characterization, In Vitro and In Vivo Evaluation.

Zou Z, Xue Y, Adu-Frimpong M, Wang C, Jin Z, Xu Y AAPS PharmSciTech. 2024; 25(8):261.

PMID: 39487315 DOI: 10.1208/s12249-024-02975-8.


References
1.
Jacobs C, Kayser O, Muller R . Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm. 2000; 196(2):161-4. DOI: 10.1016/s0378-5173(99)00412-3. View

2.
Novalic Z, van der Wal A, Leonhard W, Koehl G, Breuning M, Geissler E . Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol. 2012; 23(5):842-53. PMC: 3338286. DOI: 10.1681/ASN.2011040340. View

3.
Kesisoglou F, Panmai S, Wu Y . Nanosizing--oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007; 59(7):631-44. DOI: 10.1016/j.addr.2007.05.003. View

4.
Dubertret B, Skourides P, Norris D, Noireaux V, Brivanlou A, Libchaber A . In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002; 298(5599):1759-62. DOI: 10.1126/science.1077194. View

5.
Peltonen L, Hirvonen J . Drug nanocrystals - Versatile option for formulation of poorly soluble materials. Int J Pharm. 2017; 537(1-2):73-83. DOI: 10.1016/j.ijpharm.2017.12.005. View